A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer

NCT07714668 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

171

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Recurrent Ovarian Cancer

Interventions

DRUG: SYS6041, bevacizumab
DRUG: SYS6041, carboplatin, bevacizumab
DRUG: paclitaxel, carboplatin, bevacizumab
DRUG: SYS6041, enlonstobart, bevacizumab

Sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd.